Eyenovia, Inc. (NASDAQ:EYEN) Short Interest Update

Eyenovia, Inc. (NASDAQ:EYEN) was the recipient of a significant growth in short interest in August. As of August 15th, there was short interest totalling 3,030,000 shares, a growth of 11.8% from the July 31st total of 2,710,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the short-interest ratio is presently 2.0 days.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Eyenovia in a report on Tuesday, August 13th.

Insiders Place Their Bets

In other Eyenovia news, major shareholder Stuart M. Grant acquired 1,515,151 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The stock was bought at an average price of $0.66 per share, for a total transaction of $999,999.66. Following the purchase, the insider now owns 10,914,153 shares in the company, valued at approximately $7,203,340.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Michael M. Rowe purchased 50,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were acquired at an average price of $0.57 per share, with a total value of $28,500.00. Following the purchase, the chief executive officer now directly owns 82,927 shares in the company, valued at $47,268.39. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Stuart M. Grant acquired 1,515,151 shares of the company’s stock in a transaction on Tuesday, July 2nd. The shares were bought at an average price of $0.66 per share, with a total value of $999,999.66. Following the completion of the purchase, the insider now directly owns 10,914,153 shares of the company’s stock, valued at $7,203,340.98. The disclosure for this purchase can be found here. Insiders have acquired 1,592,222 shares of company stock worth $1,042,577 over the last 90 days. Corporate insiders own 7.10% of the company’s stock.

Institutional Trading of Eyenovia

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Leo Wealth LLC bought a new stake in Eyenovia during the 4th quarter worth about $34,000. Nations Financial Group Inc. IA ADV bought a new position in shares of Eyenovia in the 4th quarter valued at about $84,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eyenovia during the 2nd quarter worth approximately $26,000. Ground Swell Capital LLC bought a new stake in shares of Eyenovia during the second quarter worth approximately $27,000. Finally, SkyView Investment Advisors LLC bought a new stake in shares of Eyenovia during the second quarter worth approximately $87,000. 25.84% of the stock is currently owned by institutional investors and hedge funds.

Eyenovia Price Performance

NASDAQ EYEN traded down $0.03 during trading hours on Tuesday, reaching $0.52. 1,519,080 shares of the company’s stock were exchanged, compared to its average volume of 1,271,110. The firm has a fifty day moving average of $0.90 and a 200-day moving average of $0.98. The company has a current ratio of 0.46, a quick ratio of 0.27 and a debt-to-equity ratio of 3.72. Eyenovia has a one year low of $0.37 and a one year high of $2.57. The stock has a market cap of $33.60 million, a PE ratio of -0.73 and a beta of 1.77.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.